{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:35:29Z","timestamp":1790775329926,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["BMS 209-828"],"award-info":[{"award-number":["BMS 209-828"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5 \\u00D7 1000"],"award-info":[{"award-number":["5 \\u00D7 1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022-2024"],"award-info":[{"award-number":["2022-2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2023.100791","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T17:28:06Z","timestamp":1676309286000},"page":"100791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature"],"prefix":"10.1016","volume":"8","author":[{"given":"A.","family":"Boutros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.T.","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Palla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marconcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sarocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Arboscello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pronzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/fon.13.145","article-title":"Role of immunotherapy in the treatment of advanced non-small-cell lung cancer","volume":"10","author":"Rijavec","year":"2014","journal-title":"Future Oncol"},{"issue":"6382","key":"10.1016\/j.esmoop.2023.100791_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100791_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.esmoop.2023.100791_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.100791_bib7","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2023.100791_bib8","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/emp2.12209","article-title":"Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department","volume":"1","author":"Yeung","year":"2020","journal-title":"J\u00a0Am Coll Emerg Physicians Open"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib11","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2023.100791_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CAD.0000000000000903","article-title":"Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature","volume":"31","author":"Veccia","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","article-title":"Myocarditis in a patient treated with nivolumab and PROSTVAC: a case report","volume":"6","author":"Monge","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"15","key":"10.1016\/j.esmoop.2023.100791_bib15","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.esmoop.2023.100791_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.esmoop.2023.100791_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Reports Immunol"},{"issue":"27","key":"10.1016\/j.esmoop.2023.100791_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100791_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review","volume":"21","author":"Kadota","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib23","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/j.cllc.2020.01.008","article-title":"Immune checkpoint inhibitor-induced fatal myositis in a patient with squamous cell carcinoma and a history of thymoma","volume":"21","author":"Luecke","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib24","first-page":"yty149","article-title":"Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate","volume":"3","author":"Gallegos","year":"2019","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res"},{"issue":"18","key":"10.1016\/j.esmoop.2023.100791_bib26","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab","volume":"63","author":"Matson","year":"2018","journal-title":"J\u00a0Forensic Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2023.100791_bib28","first-page":"313","article-title":"Combination nivolumab\/ipilimumab immunotherapy for melanoma with subsequent unexpected cardiac arrest: a case report and review of literature","volume":"42","author":"Khoury","year":"2019","journal-title":"J\u00a0Immunother"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib30","first-page":"332","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J\u00a0Immunother"},{"issue":"11","key":"10.1016\/j.esmoop.2023.100791_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/atm.2019.04.73","article-title":"Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.esmoop.2023.100791_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.esmoop.2023.100791_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib35","first-page":"221","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.esmoop.2023.100791_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2020.107202","article-title":"Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report","volume":"46","author":"Hardy","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.esmoop.2023.100791_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report","volume":"25","author":"Mahmood","year":"2018","journal-title":"Gynecol Oncol Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib38","first-page":"282","article-title":"Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases","volume":"40","author":"Pushkarevskaya","year":"2017","journal-title":"J\u00a0Immunother"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5152\/eurjrheum.2019.18159","article-title":"Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma","volume":"6","author":"Sutaria","year":"2019","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100791_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10067-018-4373-y","article-title":"Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy","volume":"38","author":"Tauber","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment","volume":"5","author":"John","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2023.100791_bib43","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring","volume":"57","author":"Katsume","year":"2018","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino","year":"2018","journal-title":"Respirol Case Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib45","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1186\/s12885-019-6372-z","article-title":"Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10140-020-01765-6","article-title":"Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients","volume":"27","author":"Ansari-Gilani","year":"2020","journal-title":"Emerg Radiol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib47","article-title":"Unanticipated myocarditis in a surgical patient treated with pembrolizumab: a case report","volume":"14","author":"Nierstedt","year":"2020","journal-title":"A\u00a0A Pract"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib48","first-page":"937","article-title":"Immunotherapy- a double edged sword; a case of fatal myocarditis and complete response","volume":"112","author":"Peters","year":"2019","journal-title":"Ir Med J"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.52964\/AMJA.0775","article-title":"Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung","volume":"18","author":"Robinson","year":"2019","journal-title":"Acute Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2023.100791_bib51","article-title":"A\u00a0case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient","volume":"29","author":"Nakanishi","year":"2020","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.esmoop.2023.100791_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2023.100791_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-018-0388-9","article-title":"Sick sinus syndrome associated with anti-programmed cell death-1","volume":"6","author":"Hsu","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2023.100791_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2018.06.021","article-title":"Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer","volume":"101","author":"Berner","year":"2018","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.100791_bib56","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib57","doi-asserted-by":"crossref","first-page":"E580","DOI":"10.3390\/cancers11040580","article-title":"Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity-from case report to mouse model validation","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib58","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.3747\/co.26.4381","article-title":"Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib59","first-page":"e4869","article-title":"Nivolumab-induced third degree atrioventricular block in a patient with stage IV squamous cell lung carcinoma","volume":"11","author":"Bukamur","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.esmoop.2023.100791_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2019.09.009","article-title":"A\u00a0closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies","volume":"124","author":"Guo","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100791_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2023.100791_bib62","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100791_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/CMR.0000000000000598","article-title":"Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma","volume":"29","author":"M\u00f6hn","year":"2019","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"JPN J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.100791_bib66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2020.03.003","article-title":"Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade","volume":"132","author":"Tomoaia","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hemonc.2020.04.006","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Fuentes-Antr\u00e1s","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib68","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.100791_bib69","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.100791_bib70","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13691-020-00408-4","article-title":"Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma","volume":"9","author":"Hayakawa","year":"2020","journal-title":"Int Cancer Conf J"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib72","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.esmoop.2023.100791_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621858","article-title":"Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2023.100791_bib74","article-title":"Case report: simultaneous hyperprogression and fulminant myocarditis in a patient with advanced melanoma following treatment with immune checkpoint inhibitor therapy","volume":"11","author":"Barham","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.100791_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/imj.14946","article-title":"Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies","volume":"50","author":"Fazal","year":"2020","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa214","article-title":"A\u00a0different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)","volume":"4","author":"Salido Iniesta","year":"2020","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2023.100791_bib77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.31138\/mjr.31.3.355","article-title":"Arthritis and myositis in a patient treated with programmed cell death-1 (PD-1) inhibitor pembrolizumab for lung cancer","volume":"31","author":"Pagkopoulou","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CMR.0000000000000681","article-title":"Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma","volume":"30","author":"Diamantopoulos","year":"2020","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib79","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report","volume":"15","author":"Cham","year":"2021","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.esmoop.2023.100791_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-induced myocarditis overlapping myositis in a patient with metastatic thymoma: a case report","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.esmoop.2023.100791_bib81","article-title":"Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management","volume":"34","author":"Yanase","year":"2021","journal-title":"Urol Case Rep"},{"issue":"12","key":"10.1016\/j.esmoop.2023.100791_bib82","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/1759-7714.13709","article-title":"Myositis induced by durvalumab in a patient with non-small cell lung cancer: a case report","volume":"11","author":"Kobayashi","year":"2020","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2023.100791_bib83","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A\u00a0fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma","volume":"61","author":"Matsui","year":"2020","journal-title":"Int Heart J"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100791_bib84","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/imt-2020-0226","article-title":"Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations","volume":"13","author":"Zullo","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100791_bib85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor-induced myocarditis: the French working group\u2019s plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"17","key":"10.1016\/j.esmoop.2023.100791_bib86","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.100791_bib87","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients","volume":"23","author":"Sarocchi","year":"2018","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.esmoop.2023.100791_bib88","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.esmoop.2023.100791_bib89","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.34169","article-title":"Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis","volume":"151","author":"Cau","year":"2022","journal-title":"Intl J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:48:57Z","timestamp":1778834937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292300011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S205970292300011X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100791","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100791"}}